New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging

New Study: CLA May Serve Critical Role in Preventing Weight and Fat Gain During Year-End Holidays and with Normal Aging A new study published online in the International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients A recent clinical trial wherein supplementary fish oil containing omega-3 fatty acids was given to patients for a median time of 3 weeks (up to 7 weeks) prior to surgical removal of their advanced carotid atherosclerotic plaques Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients A recent clinical trial wherein supplementary fish oil containing omega-3 fatty acids was given to patients for a median time of 3 weeks (up to 7 weeks) prior to surgical removal of their advanced carotid atherosclerotic plaques Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients A recent clinical trial wherein supplementary fish oil containing omega-3 fatty acids was given to patients for a median time of 3 weeks (up to 7 weeks) prior to surgical removal of their advanced carotid atherosclerotic plaques Anti-inflammatory Effects of Omega-3 Fatty Acid Supplementation on Atherosclerotic Plaques in Patients A recent clinical trial wherein supplementary fish oil containing omega-3 fatty acids was given to patients for a median time of 3 weeks (up to 7 weeks) prior to surgical removal of their advanced carotid atherosclerotic plaques Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies. Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies. Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies. Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies. Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies. Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies. Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls). Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls). Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls). Maternal Supplementation with DHA Omega-3 Fatty Acid in Pregnancy and Infant Visual Acuity Professor Sheila Innis reported results from her clinical trial at the Congress for the International Society for the Study of Fatty Acids and Lipids (ISSFAL) being held in Cairns Australia. The women receiving DHA supplementation showed much higher levels of measured DHA in their blood samples and in their breast milk fat at 30 days post-partum (0.33% of fat as compared to only 0.19% in controls). Fish Oil Provides 24-Hour Control of Circulating Fat Levels The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals. Fish Oil Provides 24-Hour Control of Circulating Fat Levels The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals. Fish Oil Provides 24-Hour Control of Circulating Fat Levels The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals. Fish Oil Provides 24-Hour Control of Circulating Fat Levels The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals. Fish Oil Provides 24-Hour Control of Circulating Fat Levels The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals. Fish Oil Provides 24-Hour Control of Circulating Fat Levels The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals. Traditional Chinese Medicine For Diabetes Has Scientific Backing A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes. Traditional Chinese Medicine For Diabetes Has Scientific Backing A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes. Traditional Chinese Medicine For Diabetes Has Scientific Backing A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes. Traditional Chinese Medicine For Diabetes Has Scientific Backing A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes. Traditional Chinese Medicine For Diabetes Has Scientific Backing A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes. Compound in dairy products targets diabetes According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials. Compound in dairy products targets diabetes According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials. Compound in dairy products targets diabetes According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials. Compound in dairy products targets diabetes According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials. Compound in dairy products targets diabetes According to a researcher at Penn State, fatty acids commonly found in dairy products, known as conjugated linoleic acids (CLA), ave successfully treated diabetes in mice and have also shown promising results in human trials. New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone. New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone. New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone. New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone. New Study Published in Diabetes Care Shows that Supplementation with Chromium Picolinate Significantly Improves Glycemic Control and Attenuates Weight Gain Results from a new study, conducted by researchers at Pennington Biomedical Research Center (PBRC) and the University of Vermont College of Medicine, and published in the August issue of Diabetes Care, in patients with type 2 diabetes demonstrate that daily supplementation with 1000 mcg of chromium as chromium picolinate, in combination with a common oral anti-diabetic medication, improves insulin sensitivity and glucose control better than the oral anti-diabetic agent alone. New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs. New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs. New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs. New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs. New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs. Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina. Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina. Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina. Study Shows the Effectiveness of Oral Probiotic L. Rhamnosus GR-1™ and L. Reuteri RC-14™ In Treating Bacterial Vaginosis Study published in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina. Low vitamin E intake during pregnancy can lead to childhood asthma Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five. Low vitamin E intake during pregnancy can lead to childhood asthma Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five. Low vitamin E intake during pregnancy can lead to childhood asthma Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five. Low vitamin E intake during pregnancy can lead to childhood asthma Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five. Low vitamin E intake during pregnancy can lead to childhood asthma Research appearing in the September issue of of the American Journal of Respiratory and Critical Care Medicine indicates that children whose mothers had a low intake of vitamin E during pregnancy are more likely to develop wheezing and asthma by age five. Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations. Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations. Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations. Study Shows That Pine Tree Bark Reduces Diabetic Leg Ulcers Study published in the July journal of Clinical and Applied Thrombosis/Homeostasis shows that Pycnogenol heals leg ulcers in patients who suffer from diabetic leg ulcerations. Prenatal Vitamins May Reduce Risk of Brain Tumors in Children Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors. Prenatal Vitamins May Reduce Risk of Brain Tumors in Children Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors. Prenatal Vitamins May Reduce Risk of Brain Tumors in Children Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors. Prenatal Vitamins May Reduce Risk of Brain Tumors in Children Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors. Prenatal Vitamins May Reduce Risk of Brain Tumors in Children Study conducted at The Children's Hospital of Philadelphia, appearing in the September issue of Cancer Epidemiology Biomarkers & Prevention, suggests that women who take multivitamins early in pregnancy may reduce the risk that their child will develop some types of brain tumors. Study: Astaxanthin Prevents the Onset Of Asthenopia Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group. Study: Astaxanthin Prevents the Onset Of Asthenopia Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group. Study: Astaxanthin Prevents the Onset Of Asthenopia Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group. Study: Astaxanthin Prevents the Onset Of Asthenopia Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group. Study: Astaxanthin Prevents the Onset Of Asthenopia Company announces the publication of the ninth clinical study on AstaReal® astaxanthin for the reduction of asthenopia (eye fatigue). The effects of astaxanthin on eyestrain induced by accommodative dysfunction were investigated at the University of Occupational and Environmental Health, Department of Ophthalmology, Japan. Results showed a significant improvement in the astaxanthin supplemented group over the placebo group. Pine Tree Bark Reduces Diabetic Microangiopathy Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM). Pine Tree Bark Reduces Diabetic Microangiopathy Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM). Pine Tree Bark Reduces Diabetic Microangiopathy Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM). Pine Tree Bark Reduces Diabetic Microangiopathy Study published in the September edition of Angiology shows that supplementation with Pycnogenol significantly reduced diabetic microangiopathy (DM). Turmeric supplements show promise in treating arthritis New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response. Turmeric supplements show promise in treating arthritis New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response. Turmeric supplements show promise in treating arthritis New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	Research Shows Tonalin® CLA Effective When Adults are Susceptible to Adding Weight and Fat La Grange, IL (Aug. 15, 2006) – A new study¹ published online today in the prestigious International Journal of Obesity suggests that Tonalin® CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process. Cognis' Tonalin® CLA (conjugated linoleic acid) is derived from natural safflower oil, is stimulant-free, and is the most clinically tested CLA on the market. “These findings suggest that CLA may serve a critical role in reducing a common weight and fat gain that occurs with age,” said Prof. Dale Schoeller, Ph.D., University of Wisconsin-Madison, and an author of the study. “About 65 percent of the U.S. population is obese or overweight—that’s a dangerous trend on many levels. We need more research like this to help overweight individuals when they are susceptible to weight gain.” Researchers at the University of Wisconsin-Madison recognized that “small, often cumulative weight gains during the holiday season contribute to ‘weight creep’ during adulthood.” They designed a study to determine if Tonalin® CLA supplementation would help overweight adults significantly reduce body fat over a six-month period and prevent weight gain during the holiday season. Their findings showed that participants taking Tonalin® CLA safely reduced their body fat mass by 2.2 pounds and their body weight by 1.3 pounds. In comparison, those in the placebo group gained 1.5 pounds of body fat mass and 2.4 pounds of body weight during the months that are especially problematic for overweight individuals. The study confirmed that taking CLA decreases body fat mass, maintains lean body mass, and aids weight management. Unlike many other studies on body composition, participants in this trial were not restricted by a controlled diet. Furthermore, CLA was well-tolerated among participants taking it for six months just as in earlier one- and two-year trials. Study subjects included 40 healthy, overweight men and women who took 4 grams of Tonalin® CLA or a placebo per day from August 2004 to March 2005. Participants followed “healthy lifestyle” advice and Dr. Schoeller explained that while adults in this trial were only moderately active, CLA supplementation can be most effective when taken as part of a daily regimen that includes exercise and a reasonable diet. Results of this double-blind, randomized, placebo-controlled study corroborate and expand upon earlier findings by Dr. Jean-Michael Gaullier. His studies revealed that CLA reduces body fat mass in overweight but otherwise healthy adults by as much as 9 percent. CLA helped participants in his studies keep off the lost fat during the two-year trial. In this most recent study report, Dr. Schoeller referred to that research and commented on inconsistent results found in other human CLA studies. He said most of the studies with conflicting findings have been 12 weeks or shorter and thus of “insufficient duration or have utilized body composition methods that are a little less accurate than the currently accepted criterion.” The UW study is the first to use the criterion of four-compartment body composition to more accurately reflect fat changes. Christine Peggau, Tonalin® CLA Senior Marketing Manager at Cognis, said “This science-based study offers a profound new way to begin tackling the obesity trend. If we can help overweight consumers when they need it most—during the food-filled holiday season and as they age—then this research suggests we will begin to see life-long benefits.” For more information about Tonalin® CLA or to place an order, visit www.cognis.com, call 800.673.3702, e-mail cognis.custserv@cognis-us.com, or fax 513.482.3576. About Tonalin® CLA: Tonalin® CLA is the original brand of CLA and is an exclusively licensed product of the Cognis Group. CLA is a polyunsaturated, conjugated fatty acid that is a natural part of the human diet, found primarily in meat and dairy products. Cognis produces Tonalin® CLA through a proprietary process that converts linoleic acid from safflowers into CLA, providing the highest quality of CLA available. Tonalin® CLA contains the lowest amount of non-naturally occurring isomers, a patent-protected attribute that provides food and dietary supplement manufacturers with the highest levels of ingredients known to be beneficial. Tonalin® CLA is available in several product forms—such as oil and water-dispersible powder—offering manufacturers a broad range of options for their products. About Cognis: Cognis (www.cognis.com) is a worldwide supplier of innovative specialty chemicals and nutritional ingredients. The company employs about 8,000 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and delivers natural-source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, textiles, as well as agriculture and mining. The company holds a 50-percent stake in the joint venture Cognis Oleochemicals, one of the world’s leading manufacturers of oleochemicals. Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2005, Cognis recorded sales of 3.18 billion euros and an Adjusted EBITDA (earnings before interest, income taxes, depreciation, amortization and exceptional items) of 356 million euros. ### ¹ Watras AC, et al. Int. J. Obes. advance online publication, August 15, 2006 (doi:10.1038/sj.ijo.0803437) (www.nature.com/ijo/index.html)
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software